At Exscalate we master biological complexity combining our knowledge of pharmacology, artificial intelligence (AI) and supercomputing to design better drugs faster.
Our comprehensive Therapeutic Target Database (CTTD) contains all known annotated druggable targets combined with decades of studies on protein-ligand and protein-protein interactions.
Our LiGen platform is a powerful supercomputing-driven in silico simulator capable of testing the binding of 16.5 billion molecules on a target protein in just one hour.
Partner with us
and discover the
power of Exscalate
At Exscalate we leverage an open innovation approach to research and development by partnering with top tier academic institutions, industry players and start-ups.
Working in partnership with pioneering biopharma start-ups and through collaborations with ambitious European projects, Exscalate’s AI-driven supercomputing platform is accelerating drug discovery with some very promising outcomes.
Andrea Beccari, Head of Discovery Platform and Vice President at Exscalate, addressed this topic at the conference “Generative AI in Life Sciences: Navigating Wisely in a Changing World”, organized by AboutPharma.
A journey through the latest in silico advances and the hands-on experience of the European REMEDi4ALL project, showing how digital technologies are reshaping the future of drug development.
Partnerships
We have formed many successful partnerships. Together we are accelerating drug discovery.
